Literature DB >> 15623806

Not all amino acid substitutions of the common cluster E6 mutation in CYP21 cause congenital adrenal hyperplasia.

Tiina Robins1, Michela Barbaro, Svetlana Lajic, Anna Wedell.   

Abstract

More than 90% of all cases of congenital adrenal hyperplasia result from steroid 21-hydroxylase (CYP21) gene mutations. Around 95% of these are either gene deletions or any of nine sequence aberrations that have been transferred from the nearby pseudogene through apparent gene conversions. One such recurrent pseudogene-derived mutation is Cluster E6, a combination of three amino acid substitutions in exon 6: I236N, V237E, and M239K. Cluster E6 is associated with the most severe, salt-wasting form of congenital adrenal hyperplasia. We studied the functional consequences of each missense mutation individually as well as the combined effect of the three mutations comprising Cluster E6. V237E abolished enzyme function and is thus a null mutation, whereas very low but measurable activity remained for I236N. M239K, on the other hand, had no effect on enzyme activity and consequently does not contribute to the disease. Although no allele has been reported yet to contain only one or two missense mutations of Cluster E6, it is a well-known feature of CYP21 that it can harbor many different combinations of pseudogene-derived mutations. The exclusion of M239K as a disease-causing mutation is thus relevant when designing protocols for genetic diagnostics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15623806     DOI: 10.1210/jc.2004-1937

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Characterization of novel missense mutations in CYP21 causing congenital adrenal hyperplasia.

Authors:  Tiina Robins; Christine Bellanne-Chantelot; Michela Barbaro; Sylvie Cabrol; Anna Wedell; Svetlana Lajic
Journal:  J Mol Med (Berl)       Date:  2006-11-21       Impact factor: 4.599

2.  Functional studies of two novel and two rare mutations in the 21-hydroxylase gene.

Authors:  M Barbaro; L Baldazzi; A Balsamo; S Lajic; T Robins; L Barp; P Pirazzoli; E Cacciari; A Cicognani; A Wedell
Journal:  J Mol Med (Berl)       Date:  2006-03-16       Impact factor: 4.599

3.  Research Resource: Correlating Human Cytochrome P450 21A2 Crystal Structure and Phenotypes of Mutations in Congenital Adrenal Hyperplasia.

Authors:  Pradeep S Pallan; Li Lei; Chunxue Wang; Michael R Waterman; F Peter Guengerich; Martin Egli
Journal:  Mol Endocrinol       Date:  2015-07-14

4.  Structure-phenotype correlations of human CYP21A2 mutations in congenital adrenal hyperplasia.

Authors:  Shozeb Haider; Barira Islam; Valentina D'Atri; Miriam Sgobba; Chetan Poojari; Li Sun; Tony Yuen; Mone Zaidi; Maria I New
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

5.  CLIA-tested genetic variants on commercial SNP arrays: potential for incidental findings in genome-wide association studies.

Authors:  Andrew D Johnson; Anupama Bhimavarapu; Emelia J Benjamin; Caroline Fox; Daniel Levy; Gail P Jarvik; Christopher J O'Donnell
Journal:  Genet Med       Date:  2010-06       Impact factor: 8.822

6.  In Vitro Enzyme Assay of CYP21A2 Mutation (R483Q) by A Novel Method Using Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry (LC-ESI-MS/MS).

Authors:  Makoto Ono; Kenichi Kashimada; Kentaro Miyai; Toshikazu Onishi; Masatoshi Takagi; Seijiro Honma; Shuki Mizutani
Journal:  Clin Pediatr Endocrinol       Date:  2008-05-08

7.  Functional and Structural Consequences of Nine CYP21A2 Mutations Ranging from Very Mild to Severe Effects.

Authors:  Débora de Paula Michelatto; Leif Karlsson; Ana Letícia Gori Lusa; Camila D'Almeida Mgnani Silva; Linus Joakim Östberg; Bengt Persson; Gil Guerra-Júnior; Sofia Helena Valente de Lemos-Marini; Michela Barbaro; Maricilda Palandi de Mello; Svetlana Lajic
Journal:  Int J Endocrinol       Date:  2016-09-19       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.